300 mg of KSM-66 twice daily for 60 days reduces cortisol by 27.9% and perceived stress by 44%, double-blind randomized placebo-controlled trial, Chandrasekhar et al.
This study by Chandrasekhar et al. (2022), published in the Indian Journal of Psychological Medicine, is one of the most cited double-blind RCTs on the efficacy of ashwagandha (KSM-66) for the management of chronic stress. It specifically targets serum cortisol as an objective biomarker, in addition to self-evaluations of stress.
KSM-66 is an ashwagandha root extract (Withania somnifera) standardized to a high concentration of active withanolides (≥5%). It is produced by a patented extraction process that preserves the entire phytochemical spectrum of the plant, distinguishing it from leaf extracts or non-standardized powders.
The study demonstrates a dose-dependent adaptogenic effect on the HPA (hypothalamus-pituitary-adrenal) axis, with progressive normalization of cortisol levels and multidimensional improvement in quality of life.
64 adults (18–54 years) suffering from self-reported and objectively confirmed chronic stress. Inclusion: PSS score > 20/40. Exclusion: thyroid disease, corticosteroid use, pregnancy, active psychiatric conditions. 1:1 randomization.
KSM-66 300 mg morning + 300 mg evening for 60 days, with meals. Identical-appearing capsules for the placebo group (inert excipients). Compliance verified by counting returned capsules (observed adherence rate > 92%).
Morning serum cortisol (8:00 a.m.) at D0, D30, D60. DHEA-S as an indicator of cortisol/DHEA balance. Complete thyroid hormone panel. CBC, hepatic and renal panels for safety profile. Measurements at the 3 timepoints.
PSS-10 (Perceived Stress Scale), GHQ-28 (General Health Questionnaire), DASS (Depression, Anxiety, Stress Scale). Overall quality of life (WHOQOL-BREF). Sleep evaluation (PSQI). Measurements at D0, D30 and D60.
The 27.9% reduction in serum cortisol is an objective biological result, not merely a subjective perception. Chronically elevated cortisol is one of the most documented causes of accelerated aging, abdominal weight gain, sleep disorders, cognitive decline and immunosuppression. Significantly reducing it in 60 days with a well-tolerated natural product is scientifically very valuable.
The 44% reduction in perceived stress in only 2 months often exceeds what we observe with first-line drug approaches (mild anxiolytics, beta-blockers for situational anxiety), without any of the contraindications or side effects associated with them.
In our practice, we incorporate KSM-66 as an adaptogenic base for patients with functional hypercortisolism, in combination with HRV biofeedback and stress-management interventions. This synergy produces results clearly superior to each approach taken in isolation.
We systematically check the cortisol profile (salivary cortisol or morning serum cortisol) before prescribing KSM-66, then perform biological follow-up at 30 and 60 days to objectify the individual response and adjust dosage if necessary.